Cytokinetics and ALS association renew partnership

• Cytokinetics (NASDAQ:CYTK) and the ALS association announce that they have renewed their partnership.
• In 2021, Cytokinetics will continue to support and participate in several virtual events and initiatives with The ALS Association focused on continuing disease awareness and education, the company said.
• The company also said that it will potentially start a Phase 3 trial of reldesemtiv in patients with Amyotrophic lateral sclerosis (ALS), later this year.
• ALS is a progressive neurodegenerative disease that afflicts about 20K people in the United States and a comparable number of patients in Europe.